Compare BHF & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHF | ARQT |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 2018 | 2020 |
| Metric | BHF | ARQT |
|---|---|---|
| Price | $52.27 | $25.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $57.71 | $34.00 |
| AVG Volume (30 Days) | 949.9K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.06 | ★ 88.79 |
| EPS | ★ 2.84 | 0.03 |
| Revenue | ★ $6,766,000,000.00 | $376,072,000.00 |
| Revenue This Year | $27.10 | $34.85 |
| Revenue Next Year | $1.09 | $29.39 |
| P/E Ratio | ★ $18.74 | $845.00 |
| Revenue Growth | 43.23 | ★ 91.34 |
| 52 Week Low | $43.25 | $15.10 |
| 52 Week High | $66.80 | $31.77 |
| Indicator | BHF | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 17.63 | 42.14 |
| Support Level | N/A | $24.91 |
| Resistance Level | $64.01 | $28.35 |
| Average True Range (ATR) | 1.72 | 1.30 |
| MACD | -0.86 | -0.16 |
| Stochastic Oscillator | 3.86 | 12.10 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are: Annuities, that derives majority of the revenue, includes variable, fixed, index-linked, and income annuities; The life segment includes variable, term, universal, and whole life policies; The Run-off segment consists of products that are no longer actively sold and are separately managed, including ULSG, structured settlements, pension risk transfer contracts, certain company-owned life insurance policies and certain funding agreements; and The Corporate & Other segment consists of activities related to funding agreements associated with the company.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.